



Inhibitor Committee of the Association of Hemophilia Clinic Directors of Canada ToR

Mandate

- To initiate clinical research on clotting factor inhibitor
- To serve as a resource for inhibitor research initiated by other members of the AHCDC or by the AHCDC Research Committee
- To advise members of AHCDC and other physicians in Canada in managing inhibitor patients, by the generation of guidelines or treatment recommendations as appropriate

Composition and tenure

- Maximum 5-6 members
- Tenure has not been determined, and should probably be at the pleasure of the AHCDC Executive Committee. However, there should be overlap between new and departing subcommittee members

Membership

- The Chair has been selected by consensus recommendation of the members, and has rotated
- Members should have substantial clinical experience in managing inhibitor patients, and/or a basic or clinical research profile in the field, as evidenced by publications in scholarly journals

Meetings/communication

- The members will generally meet by teleconference at the call of the Chair
- The Committee will report to the membership through the Executive Committee
- It will also maintain liaison with the Research Committee when undertaking research projects

Costs

- Sufficient to hold 2 to 3 teleconferences per year
- The Committee has sometimes attracted educational grant support from biopharmaceutical companies to assist it in undertaking special projects

Current membership

- Dr. P. Moorehead (Chair)
Dr. M. Carcao,
Dr. J. Teitel,
Dr. D. Lillicrap,
Dr. G-E. Rivard,
Dr. J. St-Louis
Dr. A. Iorio,
Dr. N. Rydz